A
*
*glucagonoma|16424000
*
*
is
a rare tumor|84638005|108369006|103356009|108369006
of the alpha cells|61028007
of the pancreas|15776009|181277001
that results|394617004
in
up to a 1000-fold overproduction|26310004
of the hormone glucagon.|87568004|66603002

Alpha cell tumors|16424000
are
commonly
associated|47429007
with glucagonoma syndrome,|16424000
though
similar symptoms
are
present|52101004|246105001
in cases|398241000|413769002
of pseudoglucagonoma syndrome
in the absence|2667000|418560003
of a glucagon-secreting tumor.|66603002|108369006

Fewer|57176003
than 251 cases|398241000|413769002
of glucagonoma|16424000
have
been
described
in the literature
since
their first description|255216001|232714002
by Becker
in 1942.

Because of its rarity|84638005|103356009
(fewer|57176003
than one|421379005
in 20 million worldwide
)
,
long-term survival rates
are
as yet
unknown.|261665006

The primary physiological effect|63161005|1360005|253861007|261424001|1360005|253861007
of glucagonoma|16424000
is
an overproduction
of the peptide hormone glucagon,|52642002|87568004|66603002
which
enhances
blood glucose levels|365812005
through the activation
of anabolic|111151007
and
catabolic processes|40091007
including|55919000
gluconeogenesis
and
lipolysis respectively.|34785007

Gluconeogenesis
produces
glucose|67079006|72191006
from protein|88878007
and
amino acid materials.|52518006|260769002

It also
increases|260366006
lipolysis,|34785007
which
is
the breakdown|40091007|125366008
of fat.|271590003

The net result|255442003|394617004
is
hyperglucagonemia,|190440000
decreased blood levels|1250004|87612001|258395000|1250004|119273009|258395000|260400001|87612001|258395000|260400001|119273009|258395000|260371004|87612001|258395000|260371004|119273009|258395000
of amino acids|52518006
(hypoaminoacidemia,
anemia,|271737000
diarrhea,|398032003
and
weight loss|89362005
of 5?15 kg.|264706000|223574006|264706000|258683005|264605009|223574006|264605009|258683005

Necrolytic migratory erythema (NME)|15576007
is
a classical symptom|255333006|260997001
observed
in patients|116154003
with glucagonoma|16424000
and
is
the presenting problem|246105001|55607006
in 70%
of cases.|398241000|413769002

Associated NME|47429007
is
characterized
by the
spread|410677005
of erythematous blisters|444827008|408764000|444827008|247464001
and
swelling|423666004|442672001
across areas|42798000
subject to greater friction|263768009|263762005
and
pressure,|279046003|13543005|257893003
including|55919000
the lower abdomen,|27033000
buttocks,|46862004
perineum,|261157007|243990009
and
groin.|255575008

Diabetes mellitus also frequently|73211009|70232002
results|394617004
from the insulin|412222002
and
glucagon imbalance|66603002
that
occurs|272120004
in glucagonoma.|16424000

Diabetes mellitus|73211009
is
present|52101004|246105001
in 80?90%|264705001|264703008
of cases|398241000|413769002
of glucagonoma,|16424000
and
is
exacerbated|162473008|410661009
by preexisting insulin resistance.|48606007

A blood serum glucagon concentration|365655006|67922002|66603002|250414003|67922002|66603002|67922002|66603002|82742001
of 1000 pg/mL|259035002
or
greater|263768009
is
indicative
of glucagonoma|16424000
(
the normal range|260395002
is
50?200 pg/mL|259035002
).

However,
recent studies|6493001|110465008|6493001|224699009
have
shown
that forty percent|118582008
of patients|116154003
have
plasma glucagon levels|313864004
ranging
from 500
to 1000 pg/mL.|259035002

Increased levels|35105006|258395000|260366006|258395000
have
been
reported|229059009|223458004
in cases|398241000|413769002
of renal insufficiency,|64033007|87828008
acute pancreatitis,|197456007
hypercorticism,|47270006
hepatic diseases,|235856003
severe stress,|24484000|262188008
extended fasting,|255536004|16985007|288467006|16985007|255590007|16985007
and
familial hyperglucagonemia.|35359004|190440000|255401001|190440000

Rarely|103356009
do
these cases|398241000|413769002
result|394617004
in levels|258395000
over 500 pg/mL,|259035002
except
in the case|398241000
of patients|116154003
with hepatic diseases.[3]|235856003

Blood tests|252275004
may
also
reveal|263857004
abnormally low concentrations|371880002|82742001
of amino acids,|52518006
zinc,|86739005
and
essential fatty acids,|34325006|31979005
which
are
thought|88952004
to
play|300776002
a role
in the development|278923009
of NME.

Skin biopsies|240977001
may
also
be
taken|419652001
to
confirm|59156000
the presence|386397008
of NME.

A CBC|26604007
can
uncover|255368006
anemia,|271737000
which
is
an abnormally low level|371880002|258395000|371880002|276625007
of hemoglobin.|38082009

The tumor|108369006
itself
may
be
localized|255471002
by any number|410680006|410681005
of radiographic modalities,|258106000
including|55919000
angiography,|77343006
CT,
MRI,|113091000
PET,
and
endoscopic ultrasound.|423827005|359659005|359659005

Laparotomy|86481000
is
useful
for obtaining histologic samples|398092000|67151002|123038009
for analysis|272389005
and
confirmation|74996004
of the glucagonoma.|16424000

Heightened glucagon secretion|260365005|66603002|46242002|260366006|66603002|46242002
can
be
treated|28995006
with the administration|413454004|416118004
of octreotide,|109053000
a somatostatin analog,|395985006
which
inhibits|61511001
the release|58000006|68776005|258760001|129299003|115956009
of glucagon.|66603002

Doxorubicin|372817009
and
streptozotocin|404876000
have
also
been
used|394850002
successfully to selectively
damage|37782003
alpha cells|61028007
of the pancreatic islets.|78696007

These
do
not destroy
the tumor,|108369006
but
help
to
minimize
progression|246453008|246450006
of symptoms.

The only curative therapy|50607009|276239002|420295001|276239002
for glucagonoma|16424000
is
surgical resection,|118292001|128303001
where
the tumor|108369006
is
removed.|127485006

Resection|118292001|128303001
has
been
known|36692007
to
reverse
symptoms
in some patients.|116154003

M
:
END|261782000|422117008

anat/phys/devp/horm

noco
(d/cong/tumr,|876000
sysi/epon

proc,
drug|410942007
(A10/H1/H2/H3/H5

